SCHEMBL12623892

SCHEMBL12623892

CC(=O)c1ccc(S(=O)(=O)N2CC(CN(C)C)OC23CCN(C)CC3)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.46
▸ ALDH1A1 P00352 4/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP19A1 P11511 1/20 0.38
▸ USP5 P45974 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ AKR1B1 P15121 1/20 0.36
▸ GFER P55789 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ APOBEC3A P31941 1/20 0.35
▸ APOBEC3G Q9HC16 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12621853 0.92 ALDH1A1 (0.48) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL17553231 0.91 LIMK2 (0.39) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL12626337 0.88 LSS (0.40) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL12623903 0.88 ALDH1A1 (0.45) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL12623927 0.88 CYP19A1 (0.37) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL12626325 0.85 LIMK2 (0.44) —
SCHEMBL23159692 0.85 HSD11B1 (0.38) SMN1; SMN2USP5POLBHSD11B1KMT2A
SCHEMBL20019642 0.78 ALDH1A1 (0.34) ALDH1A1
SCHEMBL18053259 0.76 LMNA (0.41) LMNAALDH1A1NPC1MAPTRAB9A
SCHEMBL12623948 0.76 LMNA (0.57) LMNAALDH1A1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-11385221-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2022-07-12 — — US disclosed
WO-2022098700-A1 INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 CASSAVA SCIENCES, INC. (US) 2022-05-12 — — WO disclosed
US-20210389298-A1 Alzheimer's Disease Assay in a Living Patient PAIN THERAPEUTICS, INC. (US) 2021-12-16 — — US disclosed
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. 2021-04-01 — — US disclosed
EP-3791875-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS Pain Therapeutics, Inc. (US) 2021-03-17 — — EP disclosed
US-10760052-B2 Method of inhibiting tau phosphorylation Cassava Science, Inc. (US) 2020-09-01 — — US disclosed
US-20190271686-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT PAIN THERAPEUTICS, INC. 2019-09-05 — — US disclosed
US-10363239-B2 Method for inhibiting growth of cancer cells PAIN THERAPEUTICS (US) 2019-07-30 — — US disclosed
US-20140017698-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT WANG HOAU-YAN (US) 2014-01-16 — — US disclosed
US-20140017698-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT WANG HOAU-YAN (US) 2014-01-16 — — US disclosed
US-20140017699-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT CASSAVA SCIENCES, INC. 2014-01-16 — — US disclosed
US-20140017699-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT CASSAVA SCIENCES, INC. 2014-01-16 — — US disclosed
WO-2014011917-A2 A METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. (US) 2014-01-16 — — WO disclosed
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
WO-2010051497-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, FPR1 LMNA 174/4885ALDH1A1 3041/4885NPC1 2479/4885
US-10363239-B2 Method for inhibiting growth of cancer cells FLNA, FLNB, FSCN1 LMNA 1109/4885ALDH1A1 3552/4885NPC1 1832/4885
US-10760052-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT LMNA 104/4885ALDH1A1 4388/4885NPC1 2309/4885
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 LMNA 223/4885ALDH1A1 2575/4885NPC1 3168/4885
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT LMNA 104/4885ALDH1A1 4388/4885NPC1 2309/4885
US-11661580-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT LMNA 104/4885ALDH1A1 4388/4885NPC1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback